We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

By LabMedica International staff writers
Posted on 25 Sep 2026

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. More...

Troponin testing helps assess heart muscle damage, but it is usually performed in a hospital laboratory after arrival. Earlier risk assessment could help ambulance crews decide who needs emergency evaluation. A new study shows how point-of-care troponin testing combined with a clinical risk score changed prehospital triage in the Netherlands.

The study, conducted by the Rotterdam-Rijnmond ambulance service, evaluated a triage approach combining a QuidelOrtho high-sensitivity point-of-care troponin test with the HEART score. The blood test measures troponin proteins, which rise when heart muscle is damaged, and can provide results in less than 20 minutes. The HEART score then incorporates the troponin result with medical history, electrocardiogram findings, age, and other risk factors to estimate the likelihood of a major adverse cardiovascular event.

The before-and-after study enrolled 1,022 patients with chest pain between 2022 and 2025. During the before phase, 539 patients received the usual ambulance assessment, while in the after phase, 483 patients were additionally evaluated using the point-of-care troponin test and HEART score. Patients with a low HEART score and a troponin level below four nanograms per liter could remain at home or be referred to a general practitioner, provided ambulance crews did not suspect another serious condition. Follow-up lasted at least one month for all patients and exceeded six months for most.

Under usual care, 19 patients (3.5%) were left at home, compared with 165 patients (34.2%) after the new approach was introduced. With follow-up data available for 86% of participants, 109 patients (12.4%) experienced a major adverse cardiovascular event within 30 days, including 15.0% in the before phase and 9.8% in the after phase. Among patients who remained at home, one of 165 (0.6%) experienced such an event after implementation of the new approach, compared with none of the 19 patients left at home under usual care.

The researchers noted that not all eligible patients were included and that the after-phase group contained a higher proportion of low-risk patients, although adjusting for this difference did not meaningfully alter the results. Overall, the study suggests that combining point-of-care troponin testing with HEART scoring may help reduce emergency department referrals among selected patients with chest pain.

"Hospital referrals were reduced significantly, avoiding hospital overcrowding and unnecessary use of medical resources, while enabling more patients to avoid the stresses of the hospital environment. This is good for patients and good for hospitals," said Dr. Barbra Backus, a co-developer of the HEART score, while presenting the findings at the European Emergency Medicine Congress.

"Beyond emergency medical services, this approach could, with further validation, eventually be extended to other primary care settings, facilitating more efficient patient triage and resource utilization across the health care system," said Dr. Maša Sorić, head of the emergency department at University Hospital Merkur in Zagreb, Croatia, and a member of the EUSEM abstract selection committee.

Related Links
European Society for Emergency Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.